Inside 60 Degrees Pharma’s Vision: CEO Geoffrey Dow on Combatting Infectious Diseases (NASDAQ: SXTP)
Nov. 20, 2024
60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline includes development programs for Tafenoquine and Celgosivir targeting fungal, tick-borne, and other viral diseases.
Visit www.redchip.com/stocks/SXTP to learn more.
